US2004202654A1PendingUtilityA1

Methods and materials for cancer treatment

48
Assignee: MAYO FOUNDATIONPriority: Apr 9, 2001Filed: Apr 5, 2002Published: Oct 14, 2004
Est. expiryApr 9, 2021(expired)· nominal 20-yr term from priority
Inventors:Esteban Celis
A61P 35/00A61K 38/00C07K 14/4748
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and materials for inducing anti-tumor responses in melanoma patients are disclosed. These methods and materials involve gp100-derived polypeptides that contain both a helper T-cell epitope and a cytotoxic T-cell epitope.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A polypeptide comprising an HTL epitope and a CTL epitope, wherein said polypeptide is 13 to 30 amino acids long, and wherein the amino acid sequence of said polypeptide is at least 90% identical to a gp100 amino acid sequence.  
     
     
         2 . The polypeptide of  claim 1 , wherein said polypeptide comprises an amino acid sequence as set forth in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16.  
     
     
         3 . The polypeptide of  claim 1 , wherein said polypeptide binds more than one MHC class II allele.  
     
     
         4 . The polypeptide of  claim 1 , wherein said polypeptide binds HLA-DR-53 or HLA-DQw6.  
     
     
         5 . The polypeptide of  claim 1 , wherein said CTL epitope comprises MLGTHTMEV.  
     
     
         6 . The polypeptide of  claim 1 , wherein said CTL epitope comprises VSNDGPTLI.  
     
     
         7 . The polypeptide of  claim 1 , wherein said CTL epitope comprises ALNFPGSQK.  
     
     
         8 . A method for inducing an anti-tumor response in a mammal, said method comprising administering a polypeptide to said mammal, wherein said polypeptide comprises an HTL epitope and a CTL epitope, wherein said polypeptide is 13 to 30 amino acids long, and wherein the amino acid sequence of said polypeptide is at least 90% identical to a gp100 amino acid sequence.  
     
     
         9 . The method of  claim 8 , wherein said polypeptide comprises an amino acid sequence as set forth in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16.  
     
     
         10 . The method of  claim 8 , wherein said polypeptide binds more than one MHC class II allele.  
     
     
         11 . The method of  claim 8 , wherein said polypeptide binds HLA-DR-53 or HLA-DQw6.  
     
     
         12 . The method of  claim 8 , wherein said CTL epitope comprises MLGTHTMEV.  
     
     
         13 . The method of  claim 8 , wherein said CTL epitope comprises VSNDGPTLI.  
     
     
         14 . The method of  claim 8 , wherein said CTL epitope comprises ALNFPGSQK.

Join the waitlist — get patent alerts

Track US2004202654A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.